Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial.

Journal article

BACKGROUND: In patients who present with clinically isolated syndromes suggestive of multiple sclerosis, interferon beta-1a is effective in delaying evolution to clinically definite disease and in reducing MRI-measured disease activity. We aimed to assess whether this drug can also reduce the rate of brain volume decrease in such patients enrolled in the ETOMS (early treatment of multiple sclerosis) trial. METHODS: MRI data for brain volume measurements at baseline, month 12, and month 24 we...

Expand abstract

Authors: Filippi, M; Rovaris, M; Inglese, M; Barkhof, F; De Stefano, N

• Publication status: Published
• Journal: Lancet
• Volume: 364
• Issue: 9444
• Pages: 1489-1496
• Publication date: 2004-01-01
• DOI: 10.1016/s0140-6736(04)17271-1
• EISSN: 1474-547X
• ISSN: 0140-6736
• Language: English
• Keywords: Adolescent; Double-Blind Method; Humans; Interferon-beta; Adult; Female; Male; Multiple Sclerosis; Magnetic Resonance Imaging; Brain